alexa Recurrent Primary CNS Lymphoma Presenting with Central Neurogenic Hyperventilation | Open Access Journals
ISSN: 2475-3203
Journal of Brain Tumors & Neurooncology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Recurrent Primary CNS Lymphoma Presenting with Central Neurogenic Hyperventilation

Odia Y* and Kreisl TN

Department of Neurology, Columbia University Medical Center / New York Presbyterian Hospital, New York, USA

*Corresponding Author:
Odia Y
Neurological Institute of New York
710 W. 168th Street, 9th Floor, New York, USA
E-mail: [email protected]

Received date: April 02 2016; Accepted date: April 19, 2016; Published date: April 29, 2016

Citation: Odia Y, Kreisl TN (2016) Recurrent Primary CNS Lymphoma Presenting with Central Neurogenic Hyperventilation. J Brain Tumors Neurooncol 1:107. doi: 10.4172/2475-3203.1000107

Copyright: © 2016 Odia Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Brain Tumors & Neurooncology

Abstract

Background: Tumor-induced Central Neurogenic Hyperventilation (CNH) is exceedingly rare, about half resulting from Primary CNS Lymphoma (PCNSL) despite their rarity.

Results: We present a 75 year-old, immunocompetent woman with recurrent PCNSL leading to CNH. She was initially diagnosed with PCNSL via biopsy of the single enhancing left caudate focus among diffuse, nonenhancing CNS infiltrative disease without diffusion restriction or CSF or intraocular dissemination. She received 5 cycles of biweekly rituximab and methotrexate, initially dosed at 3.5 gm/m2 with procarbazine and vincristine, then dosed at 8 gm/m2 with monthly temozolomide 150 mg/m2. Repeat brain MRI revealed no residual enhancement with confluent subcortical nonenhancing signal without brainstem involvement suggesting methotrexate-related leukodystrophy. Two weeks after cytarabine consolidation, she presented with intractable emesis without gastrointestinal cause. A week later, she developed marked tachypnea without cardiopulmonary etiology. Blood glasses revealed respiratory alkalosis (maximal pH=7.67, respiration=27, pO2=241; minimum pCO2=10). She remained otherwise neurologically intact. For suspicion of CNH, she was intubated and brain MRI revealed progressive nonenhancing disease without restricted diffusion extending periventricularly from dorsal midbrain to vermis. CSF profile revealed normal protein (40 mg/dL), RBC 97/µL, WBC 3/µL (88% lymphocytes) with negative bacterial cultures, toxoplasma IgG and HSV, JC, CMV, EBV and JC PCRs. Flow cytometry and cytology revealed no lymphoma cells. Brain and body PET revealed avid FDG-uptake in the new periaqueductal nonenhancing tumor, confirming lymphoma recurrence; no extracranial disease was evident. Her CNH resolved though remission was only brief following posterior fossa radiation (30Gy, 17fx), dexamethasone 40 mg/day, and off-label nivolumab 3 mg/kg q 2 weeks. Repeat brain MRI revealed diffuse cerebral nonenhancing disease progression at 4 months after recurrence. She died shortly after transfer to hospice.

Conclusion: This represents the first recurrent PCNSL leading to CNH, which was a presenting symptom in all prior PCNSL cases reported and lead to death in the majority.

Keywords

CNS lymphoma; Central neurogenic hyperventilation; Radiation

Introduction

Tumor-induced central neurogenic hyperventilation (CNH) is exceedingly rare. CNH is defined by hyperventilation with low arterial PaCO2, high arterial PaO2, and high arterial pH without drug or metabolic causes [1,2]. Most cases of tumor-induced CNH result from primary CNS despite their rarity, comprising only 4% of primary CNS tumors [2,3]. Tumor-induced CNH resulted from CNS lymphoma in nearly 60% of tumor-induced CNH [2,4-15]. Most tumor-induced CNH results from infiltrating tumor in the pons or medulla, less commonly in the setting of diffuse cerebral disease [2,5]. The presumed mechanism is activation of respiratory centres and central chemoreceptors [2]. All previously reported cases presented with CNH at diagnosis. We present an immunocompetent woman with previously diagnosed PCNSL presenting with CNH at first recurrence. Tumor-induced CNH proved uniformly fatal in essentially all cases.

Case Presentation

A 75 year-old, immunocompetent woman presented with months of progressive dementia and aphasia. A brain MRI revealed diffuse cerebral, predominantly subcortical, non-enhancing disease (Figure 1A). There was a single site of enhancement in the left caudate and negligible diffusion restriction noted (Figures 1B-1C). Stereotactic biopsy of single enhancing lesion revealed pathology consistent with diffuse large B cell lymphoma. Hematoxylin and Eosin (H&E) showed large atypical lymphoid cells in an angiocentric pattern and with scant cytoplasm, large pleomorphic nuclei with clumped chromatin, nuclear moulding and occasionally prominent nucleoli (Figure 2A). Scattered mitoses were seen. Immunohistochemistry was positive for CD20 (Figure 2B) and MUM1. Subsets were positive for BCL2 and BCL6 and few for CD10. Small mature CD3 T lymphocytes infiltrate was detected. The Ki67 proliferation index was as high as 80-90% (Figure 2C).

brain-tumors-neurooncology-Brain-imaging

Figure 1: Brain imaging findings. Brain MRI findings were atypical for primary CNS lymphoma (PCNSL), defined by predominantly non enhancing disease on fluid attenuation inversion recovery (FLAIR) images (A,D,E,F,H) and no associated restricted diffusion was ever noted (C). FLAIR diseases was restricted to cerebral hemispheres at presentation (A), limited to periaqueductal grey brainstem at recurrence (E-F) and diffuse but predominantly supratentorial prior to death (H). The single faintly enhancing focus in left caudate (B) at presentation was targeted for biopsy. Remission was notable for residual FLAIR signal restricted to subcortical white matter and consistent with methotrexate-induced leukodystrophy (D). The recurrent disease in the brainstem presenting with central neurogenic hyperventilation was avid on fluorodeoxyglucose positron emission tomography (FDG-PET, G).

brain-tumors-neurooncology-brain-biopsy

Figure 2: Pathology of brain biopsy. H&E shows large atypical lymphoid cells in an angiocentric pattern and with scant cytoplasm, large pleomorphic nuclei with clumped chromatin, nuclear molding, and occasionally prominent nucleoli (A, 4x). Scattered mitoses seen. Immunostaining: positive for CD20 (B, 4x), MUM1; subset positive for BCL2, BCL6; few positive for CD10. Small mature CD3 T lymphocytes infiltrate lesion. Ki67 index up to 80-90% (C, 4x).

Brain and body Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) revealed no systemic involvement, consistent with Primary CNS Lymphoma (PCNSL). Flow cytometry and cytology revealed no Cerebrospinal Fluid (CSF) dissemination. A bone marrow biopsy revealed mild B-cell lymphocytosis inconclusive for marrow involvement. She was treated with 5 cycles of biweekly intravenous rituximab (500 mg/m2) and methotrexate. Methotrexate was increased from 3.5 to 8.0 gm/m2 while the initial procarbazine (100 mg/m2) and vincristine 2 mg was switched to monthly temozolomide (150 mg/m2) for a total of 2.5 months of therapy. After repeat brain MRI revealed remission (Figure 1D), she underwent consolidation therapy with cytarabine (3 gm/m2 day 1-2, q3 weeks). Over the course of this therapy, she improved clinically with a dramatic improvement in her initial encephalopathy, once again living independently.

At 4 months from diagnosis and shortly after consolidation therapy, she developed intractable emesis without clear gastrointestinal cause and hyperventilation without cardiopulmonary etiology. Serial blood glasses marked revealed respiratory alkalosis (maximal pH=7.67, respiration=27, pO2=241; minimum pCO2=10). She remained otherwise neurologically intact. For suspicion of central neurogenic hyperventilation (CNH), she was intubated and brain MRI performed. While there was no clear supratentorial disease progression (Figure 1E), there was new non enhancing FLAIR disease extending from dorsal midbrain to the vermis (Figure 1F). Repeat brain FDG-PET revealed high glucose uptake associated with the new FLAIR disease in the pontine tegmentum (Figure 1G), consistent with recurrent PCNSL. CSF profile revealed normal protein (40 mg/dL), RBC 97/μL, WBC 3/μL (88% lymphocytes) with negative bacterial cultures, toxoplasma IgG and HSV, JC, CMV, EBV and JC PCRs. Flow cytometry and cytology again revealed no lymphoma cells.

To palliate and spare cognitive neurotoxicity, she was treated with involved field radiation to posterior fossa radiation (30Gy in 17 fractions), dexamethasone 40 mg/day, and off-label nivolumab 3 mg/kg q2 weeks with resolution of CNH. Disease remission was only brief. By 4 months after recurrent PCNSL presenting with CNH, brain MRI revealed diffuse non enhancing disease progression, including the brainstem but more pronounced in the cerebral hemispheres (Figure 1H). She was transferred to hospice and died shortly after 9 months after her initial diagnosis.

Discussion

Central Neurogenic Hyperventilation (CNH) is exceedingly rare and portends poor prognosis in reported cases. Despite their rarity, comprising only 1% of all CNS tumors, CNS Lymphoma (CNSL) leads to 58% (15/26) of reported cases, mostly (13/15) Primary CNS Lymphoma (PCNSL) [2,4-15]. The remaining cases were comprised of 31% (8/26) gliomas [16-23], <4% (1/26) medulloblastoma [24], <4% (1/26) ganglioglioma [25] and <4% (1/26) invasive laryngeal carcinoma [26]. 77% (20/26) of tumor-induced CNH cases resulted from direct tumor infiltration into the pontine tegmentum and medulla, leading to activation of respiratory centres and central chemoreceptors [2]. The remaining cases had diffuse cerebral disease, mostly CNS lymphoma cases [2,5]. We present the first case of PCNSL presenting with CNH at recurrence. All prior cases of tumor-induced CNH presented at the time of diagnosis. CNH should raise suspicion of CNS lymphoma in undiagnosed patients and suggest recurrence in confirmed cases of CNS lymphoma. Antineoplastic therapy is vital for controlling PCNSL-induced CNH. Survival is uniformly dismal after presenting with tumor-induced CNH.

Conclusion

We present the first case of recurrent primary CNS lymphoma leading to Central Neurogenic Hyperventilation (CNH). CNH was a presenting symptom in all previously reported cases of CNS lymphoma, comprising nearly 60% of reported cases of tumor-induced CNH despite their rarity. Tumor-induced CNH raises the probability of CNS lymphoma in undiagnosed cases and of recurrence in diagnosed cases. Tumor-induced CNH predicts short-interval death in most cases.

Practice Points

• Primary CNS lymphoma comprises ~1% of all CNS tumors and ~2.3% of primary CNS tumors.

• Tumor-induced central neurogenic hyperventilation (CNH) is exceedingly rare and uniformly fatal.

• Tumor-induced CNH is caused by CNS lymphoma in nearly 60% of reported cases.

• CNH should raise suspicion of CNS lymphoma in undiagnosed patients and suggest recurrence in confirmed cases of CNS lymphoma.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 7952
  • [From(publication date):
    June-2016 - Aug 22, 2017]
  • Breakdown by view type
  • HTML page views : 7895
  • PDF downloads :57
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords